

Table 2.2. Cohort studies of combined estrogen–progestogen menopausal therapy and breast cancer

| Reference, Location, Period | Age at recruitment (years) | Size of cohort | Average of follow-up (years) | Total no. of cases | Histo-logical diagnosis | Sub-sites | Hormone therapy (type/ regimen) | No. of cases | Relative risk (95% CI) | Comments | |
|--|----------------------------|------------------|------------------------------|--------------------|-------------------------|------------|---------------------------------|--------------|------------------------|---|--|
| Stahlberg <i>et al.</i> (2004), Denmark, 1993–1999 | 44+ | 10 874 | ? | 244 | Invasive | All Ductal | All | 244 | | Adjusted for benign breast disease (0, yes; 1, no) and menopausal age (0, > 55 yrs; 1, 55+ yrs). prog-P = progesterone-like progestin; test-P = testosterone-like progestin | |
| | | | | | | | Ductal | 172 | | | |
| | | | | | | | Never | 78 | 1.0 | | |
| | | | | | | | Past | 31 | 1.16 (0.76–1.77) | | |
| | | | | | | | Current | 103 | 2.24 (1.81–3.26) | | |
| | | | | | | | E+prog-P cyclical | | | | |
| | | | | | | | All | 20 | 3.02 (1.80–5.05) | | |
| | | | | | | | Ductal | 15 | 3.10 (1.96–5.67) | | |
| | | | | | | | E+test-P cyclical | | | | |
| | | | | | | | All | 32 | 1.94 (1.26–3.00) | | |
| | | | | | | | Ductal | 26 | 2.15 (1.31–3.54) | | |
| | | | | | | | E+test-P continuous | | | | |
| All | 23 | 4.16 (2.56–6.75) | | | | | | | | | |
| Ductal | 17 | 4.10 (2.29–7.30) | | | | | | | | | |
| Fournier <i>et al.</i> (2005), France, 1990–2000 | 52.8 (mean) | 54 548 | 5.8 | 948 | Invasive | | Estrogens + oral progestogens | 323 | 1.3 (1.1–1.5) | Adjusted for time since menopause, BMI (continuous), age at menopause (continuous), parity and age at first full-term pregnancy (nulliparous/first full-term pregnancy at age <30/first full term pregnancy at age ≥30, 1 child/ first full term pregnancy at age ≥30, 2 or more children), familial history of breast cancer in sisters, mother, children (no/1/more than 1), familial history of breast cancer in other relatives (yes/no), personal history of benign breast disease (yes/no), use of oral progestogens before menopause (none or less than 2 years of use/2 to 5 years of use/more than 5 years of use), ever use of oral contraceptives and previous mammography (as time-dependent variable). | |
| | | | | | | | Estrogens + synthetic progestin | 268 | 1.4 (1.2–1.7) | | |
| | | | | | | | Transdermal/percutaneous route | 187 | 1.4 (1.2–1.7) | | |
| | | | | | | | Oral route | 80 | 1.5 (1.1–1.9) | | |

Table 2.2. Cohort studies of combined estrogen–progestogen menopausal therapy and breast cancer

| Reference, Location, Period | Age at recruitment (years) | Size of cohort | Average of follow-up (years) | Total no. of cases | Histo-logical diagnosis | Sub-sites | Hormone therapy (type/ regimen) | No. of cases | Relative risk (95% CI) | Comments |
|--|----------------------------|--------------------|------------------------------|--------------------|-------------------------|-----------|---|--------------------------------------|---|--|
| Lee <i>et al.</i> (2006), USA, 1993–2002 | 45–75 | 55 371 | 7.3 | 1615 | Invasive | | Never | 642 | 1.00 | Adjusted for time on study. Also adjusted for ethnicity, age at menarche, age at first birth, number of children, age and type of menopause, BMI, alcohol consumption, and family history |
| | | | | | | | Current E + P | | | |
| | | | | | | | >0 to <5 | 53 | 1.43 (1.06–1.93) | |
| | | | | | | | 5 to <10 | 182 | 1.82 (1.53–2.17) | |
| | | | | | | | 10+ | 232 | 2.18 (1.86–2.56) | |
| | | | | | | | Past E + P | | | |
| | | | | | | | >0 to <5 | 104 | 1.01 (0.82–1.24) | |
| 5 to <10 | 17 | 2.08 (1.27–3.42) | | | | | | | | |
| 10+ | 4 | 0.91 (0.37–2.21) | | | | | | | | |
| Rosenberg, <i>et al.</i> (2006a), USA, 1995–2003 | 40+ | 32 559 Black women | 8.0 | 615 | Invasive | | Never | 364 | 1.0 | Adjusted for age at baseline in 1-year intervals, menopausal status (premenopausal, naturally menopausal, bilateral oophorectomy, and hysterectomy), and age at menopause or hysterectomy. |
| | | | | | | | Ever | 251 | 1.09 (0.90–1.32) | |
| | | | | | | | Recent | 210 | 1.15 (0.94–1.40) | |
| | | | | | | | Past | 40 | 0.94 (0.67–1.32) | |
| | | | | | | | Estrogen + progestin | 67 | 1.28 (0.97–1.70) | |
| | | | | | | | <5 | 35 | 1.13 (0.79–1.63) | |
| ≥5 | 24 | 1.45 (0.94–2.23) | | | | | | | | |
| Corrao <i>et al.</i> (2008), Italy, 1998–2005 | 45–75 | 73 505 | Not specified | 1296 | | | Transdermal estradiol Oral estradiol | 1.27 (1.07–1.51) 2.14 (1.43–3.21) | Not adjusted Only 10% had undergone hysterectomy | |